Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,681 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,681 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36. Following the completion of the sale, the chief operating officer now directly owns 237,640 shares of the company’s stock, valued at $9,876,318.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Stock Up 0.2 %

NASDAQ:TWST opened at $45.52 on Friday. Twist Bioscience Co. has a fifty-two week low of $15.85 and a fifty-two week high of $60.90. The stock’s 50-day moving average is $43.65 and its two-hundred day moving average is $45.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience in the 3rd quarter worth approximately $43,992,000. Point72 Asset Management L.P. grew its holdings in shares of Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares in the last quarter. Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after acquiring an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in Twist Bioscience during the second quarter valued at $9,462,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TWST. Barclays cut their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Finally, Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.